Martingale Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Martingale Asset Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-69,945	Closed	-$1.41M	–	865
2026 Q1	$1.41M	Buy	69,945 +39,006	+126%	+$629K	0.04%	415
2025 Q4	$500K	Buy	+30,939	New	+$410K	0.01%	608

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Martingale Asset Management's KALV Position: Q2 2026 in Review

Martingale Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 69,945 shares — an estimated $1.41M sold.

Martingale Asset Management first reported a position in KALV in Q4 2025 and held it in 2 quarters. The position peaked at $1.41M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Martingale Asset Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Martingale Asset Management sold 69,945 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.41M.
Martingale Asset Management first reported a position in KalVista Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Martingale Asset Management's KalVista Pharmaceuticals position peaked at $1.41M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.